BriaCell Therapeutics Corp.
TSX:BCT.TOBiotechnology
+$0.94 today
- Market cap
- $50.02M
- Beta
- 1.53
- P/E (TTM)
- -0.3
- EPS (TTM)
- -$4.23
Volume 0.00M
Average 0.01M
Returns on capital
BriaCell Therapeutics Corp. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-148.4%
avg -14.0%
ROIC
-155.3%
avg 222.1%
ROA
-122.6%
avg -268.1%
Analysis
ROA is currently the strongest return metric at -122.6% versus its period average of -268.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
William V. Williams | Chief Executive Officer, President & Director | CAD 991.08K | 71 | — | — |
Gadi Levin | Chief Financial Officer & Corporate Secretary | CAD 745.49K | 53 | — | — |
Giuseppe Del Priore | Chief Medical Officer | CAD 686.57K | 64 | — | — |
Miguel A. Lopez-Lago | Chief Scientific Officer | CAD 623.21K | 56 | — | — |
Charles Louis Wiseman FACP | Founder, Principal Research Advisor & Member of Scientific Advisory Board | CAD 335.79K | 79 | — | — |
Compensation is shown in the reported currency; data updated Sep 17, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Competitors
Who does BriaCell Therapeutics Corp. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
No competitor data available.
Questions
Management questions
Common questions about BCT.TO's management, answered from reported figures.
Who manages BCT.TO?
BriaCell Therapeutics Corp. (BCT.TO) lists 5 active executives. The top listed executive is Miguel A. Lopez-Lago, Chief Scientific Officer.
Continue the stock analysis
Jump to another research area for this company.